Chronic treatment with cyclosporine affects systemic purinergic parameters, homocysteine levels and vascular disturbances in rats

Chemico-Biological Interactions

Volumn 188, Issue 1, 2010, Pages 15-20

  Böhmer, Ana Elisa ^a   Brum, Liz Marina P ^b   Souza, Débora Guerini ^a   Corrêa, André Mendes Ribeiro ^a   Oses, Jean Pierre ^c   Viola, Giordano Gubert ^a   Saraiva, Paulo Jaconi ^a   Driemeier, David ^a   Portela, Luis Valmor ^a   Souza, Diogo Onofre ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FUC   (Brazil)

^c University of Pelotas   (Brazil)

Author keywords

Adenosine; Cyclosporine; Ecto nucleotidase; Homocysteine; Vascular disease

Indexed keywords

ADENINE NUCLEOTIDE; ADENOSINE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CYCLOSPORIN A; ECTO 5' NUCLEOTIDASE; HOMOCYSTEINE; CYCLOSPORIN; PURINERGIC RECEPTOR;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HYDROLYSIS; LONG TERM CARE; MALE; NONHUMAN; RAT; TOXICITY TESTING; VASCULAR DISEASE; ANIMAL; BLOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; WISTAR RAT;

ADENINE NUCLEOTIDES; ANIMALS; AORTA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; HOMOCYSTEINE; HYDROLYSIS; MALE; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC;

RATTUS; RATTUS NORVEGICUS; ZEA MAYS;

EID: 77956173965     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.06.011     Document Type: Article

References (44)

1. Kahan B.D. Forty years of publication of transplantation proceedings-the second decade: the cyclosporine revolution. Transplant Proc. 2009, 41(5):1423-1437.
2. Nickel T., Schlichting C.L., Weis M. Drugs modulating endothelial function after transplantation. Transplantation 2006, 82(1 Suppl.):S41-S46.
3. Christians U., Schmitz V., Schoning W., Bendrick-Peart J., Klawitter J., Haschke M. Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality, and challenges. Ther. Drug Monit. 2008, 30(2):151-158.
4. Weis M., von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 1997, 96(6):2069-2077.
5. Kendrick E. Cardiovascular disease and the renal transplant recipient. Am. J. Kidney Dis. 2001, 38(6 Suppl. 6):S36-S43.
6. Serkova N.J., Christians U., Benet L.Z. Biochemical mechanisms of cyclosporine neurotoxicity. Mol. Interv. 2004, 4(2):97-107.
7. Belperio J.A., Ardehali A. Chemokines and transplant vasculopathy. Circ. Res. 2008, 103(5):454-466.
8. Moien-Afshari F., McManus B.M., Laher I. Immunosuppression and transplant vascular disease: benefits and adverse effects. Pharmacol. Ther. 2003, 100(2):141-156.
9. Arnadottir M., Hultberg B., Vladov V., Nilsson-Ehle P., Thysell H. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996, 61(3):509-512.
10. Malinow M.R. Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases. J. Nutr. 1996, 126(4 Suppl.):1238S-1243S.
11. Antoniades C., Antonopoulos A.S., Tousoulis D., Marinou K., Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur. Heart J. 2009, 30(1):6-15.
12. Mayer E.L., Jacobsen D.W., Robinson K. Homocysteine and coronary atherosclerosis. J. Am. Coll. Cardiol. 1996, 27(3):517-527.
13. Potter K., Hankey G.J., Green D.J., Eikelboom J., Jamrozik K., Arnolda L.F. The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. BMC Cardiovasc. Disord. 2008, 8:24.
14. Mudd S.H., Levy H.L., Skovby F. Disorders of transulfuration. The Metabolic and Molecular Basis of Inherited Disease 2001, 1279-1327. McGraw-Hill, New York. A.L. Beaudet, C.R. Scriver, W.S. Sly, D. Valle (Eds.).
15. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J. Clin. Invest. 1996, 98(1):5-7.
16. Riksen N.P., Rongen G.A., Yellon D., Smits P. Human in vivo research on the vascular effects of adenosine. Eur. J. Pharmacol. 2008, 585(2-3):220-227.
17. Ralevic V., Burnstock G. Involvement of purinergic signaling in cardiovascular diseases. Drug News Perspect. 2003, 16(3):133-140.
18. Cristalli G., Vittori S., Thompson R.D., Padgett W.L., Shi D., Daly J.W., Olsson R.A. Inhibition of platelet aggregation by adenosine receptor agonists. Naunyn Schmiedebergs Arch. Pharmacol. 1994, 349(6):644-650.
19. Born G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 194:927-929.
20. Coade S.B., Pearson J.D. Metabolism of adenine nucleotides in human blood. Circ. Res. 1989, 65(3):531-537.
21. Robson S.C., Wu Y., Sun X., Knosalla C., Dwyer K., Enjyoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin. Thromb. Hemost. 2005, 31(2):217-233.
22. Mishra S.K., Braun N., Shukla V., Fullgrabe M., Schomerus C., Korf H.W., Gachet C., Ikehara Y., Sevigny J., Robson S.C., Zimmermann H. Extracellular nucleotide signaling in adult neural stem cells: synergism with growth factor-mediated cellular proliferation. Development 2006, 133(4):675-684.
23. Oses J.P., Cardoso C.M., Germano R.A., Kirst I.B., Rucker B., Furstenau C.R., Wink M.R., Bonan C.D., Battastini A.M., Sarkis J.J. Soluble NTPDase: an additional system of nucleotide hydrolysis in rat blood serum. Life Sci. 2004, 74(26):3275-3284.
24. 2+-stimulated ATPase activity. Anal. Biochem. 1986, 157(2):375-380.
25. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
26. Schmidt A.P., Bohmer A.E., Antunes C., Schallenberger C., Porciuncula L.O., Elisabetsky E., Lara D.R., Souza D.O. Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br. J. Pharmacol. 2009, 156(1):163-172.
27. Elisa Bohmer A., Ribeiro Correa A.M., de Souza D.G., Knorr L., Hansel G., Gustavo Corbellini L., Driemeier D., Valmor Portela L., Onofre Souza D. Long-term cyclosporine treatment: evaluation of serum biochemical parameters and histopathological alterations in Wistar rats. Exp. Toxicol. Pathol. 2009.
28. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274(13):1049-1057.
29. Miner S.E., Evrovski J., Cole D.E. Clinical chemistry and molecular biology of homocysteine metabolism: an update. Clin. Biochem. 1997, 30(3):189-201.
30. Wilcken D.E., Gupta V.J., Betts A.K. Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin. Sci. (Lond.) 1981, 61(6):743-749.
31. Berger P.B., Jones J.D., Olson L.J., Edwards B.S., Frantz R.P., Rodeheffer R.J., Kottke B.A., Daly R.C., McGregor C.G. Increase in total plasma homocysteine concentration after cardiac transplantation. Mayo Clin. Proc. 1995, 70(2):125-131.
32. Bostom A.G., Gohh R.Y., Tsai M.Y., Hopkins-Garcia B.J., Nadeau M.R., Bianchi L.A., Jacques P.F., Rosenberg I.H., Selhub J. Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients. Arterioscler. Thromb. Vasc. Biol. 1997, 17(10):1894-1900.
33. Cole D.E., Ross H.J., Evrovski J., Langman L.J., Miner S.E., Daly P.A., Wong P.Y. Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients. Clin. Chem. 1998, 44(11):2307-2312.
34. Stanger O., Herrmann W., Pietrzik K., Fowler B., Geisel J., Dierkes J., Weger M. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z. Kardiol. 2004, 93(6):439-453.
35. Bohmer A.E., Pochmann D., Sarkis J.J. In vitro effect of homocysteine on nucleotide hydrolysis by blood serum from adult rats. Chem. Biol. Interact. 2006, 160(2):159-164.
36. Riksen N.P., Rongen G.A., Blom H.J., Boers G.H., Smits P. Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia. Clin. Chem. Lab. Med. 2005, 43(10):1001-1006.
37. Riksen N.P., Rongen G.A., Boers G.H., Blom H.J., van den Broek P.H., Smits P. Enhanced cellular adenosine uptake limits adenosine receptor stimulation in patients with hyperhomocysteinemia. Arterioscler. Thromb. Vasc. Biol. 2005, 25(1):109-114.
38. Chen Y.F., Li P.L., Zou A.P. Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation 2002, 106(10):1275-1281.
39. Deussen A. Metabolic flux rates of adenosine in the heart. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362(4-5):351-363.
40. Riksen N.P., Rongen G.A., Blom H.J., Russel F.G., Boers G.H., Smits P. Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovasc. Res. 2003, 59(2):271-276.
41. Böhmer A.E., Souza D.G., Hansel G., Brum L.M.B.P., Souza D.O. Long-term cyclosporine treatment in non transplanted rats and metabolic risk factors of vascular diseases. Chem. Biol. Interact. 2010, 185(1):53-58.
42. Imai M., Takigami K., Guckelberger O., Enjyoji K., Smith R.N., Lin Y., Csizmadia E., Sevigny J., Rosenberg R.D., Bach F.H., Robson S.C. Modulation of nucleoside [correction of nucleotide] triphosphate diphosphohydrolase-1 (NTPDase-1)cd39 in xenograft rejection. Mol. Med. 1999, 5(11):743-752.
43. Gendron F.P., Benrezzak O., Krugh B.W., Kong Q., Weisman G.A., Beaudoin A.R. Purine signaling and potential new therapeutic approach: possible outcomes of NTPDase inhibition. Curr. Drug Targets 2002, 3(3):229-245.
44. Yegutkin G.G. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim. Biophys. Acta 2008, 1783(5):673-694.